TauRx Announces Results from Phase 3 Alzheimer's Disease Study, LUCIDITY, Assuring Path for Regulatory Submissions


  • For folks with early Alzheimer’s (MCI), HMTM remedy resulted in sustained enchancment in cognition over pre-treatment baseline, and normalisation of mind atrophy to a price just like wholesome people
  • For folks with delicate to average Alzheimer’s, HMTM stabilised cognition and performance and diminished price of mind atrophy in comparison with historic matched people with AD
  • HMTM is an oral drug with a powerful security profile, having no danger of amyloid associated imaging abnormalities
  • TauRx will current the Phase 3 findings on the Clinical Trials in Alzheimer’s Disease (CTAD) convention on Wednesday, thirtieth November 2022, in San Francisco

ABERDEEN, Scotland and SINGAPORE, Oct. 6, 2022 TauRx Pharmaceuticals Ltd is a worldwide chief in tau-based analysis in Alzheimer’s illness (AD). Pathological aggregation of Tau correlates with scientific illness severity and mind atrophy. It is a trademark of the illness now usually recognised as an vital potential goal for treating AD.

/PRNewswire/ — Hydromethylthionine mesylate (HMTM) is a potent inhibitor of Tau aggregation pathology which is taken orally. The Phase 3 LUCIDITY research in contrast HMTM 16 mg/day with methylthioninium chloride (MTC) given at a dose of 4 mg twice weekly, the minimal required to stop bias arising from potential urinary discolouration. The research was performed in 598 sufferers with AD severity ranging from Mild Cognitive Impairment (MCI) via to the average stage of illness.

TauRx has now accomplished the primary 12-month double-blind section of the trial. The second 12-month open label interval is ongoing, throughout which all contributors obtain HMTM 16 mg/day. All contributors have been required to have a optimistic amyloid-PET scan and to not be taking normal symptomatic remedies for AD.

Of these receiving MTC 4 mg twice weekly, the bulk have been unexpectedly discovered to have blood ranges of energetic drug above the edge wanted to provide a scientific impact. In the absence of a real placebo, the trial as designed couldn’t decide outcomes on major scientific endpoints relative to a therapeutically inactive placebo as prespecified. In mild of the proof now accessible, TauRx doesn’t imagine {that a} legitimate blinded placebo-controlled trial of HMTM with scientific endpoints is technically possible. TauRx has due to this fact analysed the information when it comes to the connection between blood focus of drug and remedy impact, change from pre-treatment baseline, and comparisons towards historic controls accessible from intently matched information from the Alzheimer’s Neuroimaging Initiative (ADNI).

See also  LUCIDITY phase 3 topline data presented at CTAD for HMTM - the only oral anti-Tau therapy in late-stage development

The total baseline MMSE rating was 21 for the research inhabitants spanning MCI via to average illness. There was minimal decline over the primary 12 months in contributors receiving the 16 mg/day dose on each coprimary cognitive and purposeful endpoints (1.3 ADAS-cog11 items and -1.0 ADCS-ADL23 items). The anticipated decline over 12 months in an untreated inhabitants could be roughly 5 items on each scales.

In the 105 contributors with MCI (baseline MMSE rating 23) receiving the 16 mg/day dose, there was statistically vital cognitive enchancment of two items over the pre-treatment baseline at 6 months (p=0.0002), 12 months (p=0.0391) and 18 months (p=0.0473) on the ADAS-cog13 scale. The imply change on the instrumental actions of each day dwelling subscale of ADCS-ADL additionally remained above the pre-treatment baseline at 6, 12 and 18 months.

In the 147 contributors with delicate to average AD (baseline MMSE 20) receiving 16 mg/day, there was a 2.5 unit cognitive decline within the first 9 months and no additional decline over the next 9 months. The purposeful decline on the ADCS-ADL scale was -2 items at 12 months and -3 items at 18 months representing a discount in decline of about 75% relative to a broadcast meta-analysis of publicly accessible placebo decline information from historic trials in delicate to average AD.

Statistically vital reductions in illness development as measured by change in cognitive perform (p=0.0008) and mind atrophy (p<0.0001) have been confirmed by comparisons of contributors receiving the 16 mg/day dose towards ADNI topics who have been closest to the research inhabitants by age and scientific severity. The variations remained statistically vital in each MCI and AD subgroups.  As anticipated, LUCIDITY trial contributors with MCI entered the research with extra mind atrophy than ADNI wholesome getting old topics and in line with ADNI MCI topics. Those handled with HMTM 16 mg/day had a price of development of mind atrophy that was considerably lower than in ADNI MCI topics (p<0.0001) and similar to that seen in ADNI wholesome getting old topics. 

Recent trials which have examined remedies focusing on amyloid have been performed in comparable or milder populations than the MCI group within the LUCIDITY trial. When HMTM is in comparison with publicly accessible placebo decline information from these research as a benchmark, the remedy results on cognitive and purposeful decline are about three-fold bigger over 18 months. The profit seen with HMTM is clinically significant for folks with Alzheimer’s.

See also  Gray Announces Additional Voluntary Paydown of Debt

The security profile seen in LUCIDITY stays sturdy and in line with earlier revealed HMTM trial information. There have been no treatment-related severe adversarial occasions or proof of amyloid associated imaging abnormalities (ARIA).

On the end result of the present information evaluation, Professor Claude Wischik, Executive Chairman and co-founder of TauRx, explains, “This is the primary time any remedy has produced proof of sustained enchancment over the person’s personal pre-treatment baseline lasting 18 months at an early clinically detectable stage of AD, and stabilization of illness development at extra extreme levels. The ends in AD affirm revealed findings from two earlier HMTM Phase 3 trials. The availability of an accessible oral remedy which doesn’t require costly monitoring over routine scientific care opens up a chance to intervene earlier than the onset of the cognitive and purposeful decline that result in lack of independence.

“Tau pathology of the disease is now recognized as an important target for treatment, and it is encouraging that cognitive improvement is seen at such an early stage of the disease with a drug targeting Tau. The field has focused mainly on amyloid as a target for early intervention. Our data are consistent with the evidence that Tau pathology begins at least 20 years before clinical symptoms appear and is a viable first-line target for treatment.”

To help with subsequent levels, TauRx has appointed strategic regulatory advisors within the UK, US and Canada, alongside naming Dr Richard Stefanacci, a longtime international key opinion chief in Alzheimer’s, as Chief Medical Officer. Dr Stefanacci is a US-based Internist and fellowship skilled Geriatrician who’s an energetic doctor caring for folks with Alzheimer’s each day.

Dr Stefanacci commented: “These data support our ability to pursue regulatory submissions. We look forward to making a significant difference addressing this global unmet need with a medication that is affordable, easy to administer, and safe. I’m very pleased to be joining the team and supporting the work we’re undertaking to achieve our mission of bringing treatments to people affected by neurodegenerative diseases caused through protein aggregation – Alzheimer’s is just the beginning.”

On the appointment of Dr Stefanacci, Professor Claude Wischik mentioned, (*3*)

See also  Lamborghini announces the arrival of three new models


LUCIDITY is the one late-stage scientific trial particularly focusing on the tau pathology of Alzheimer’s. Aggregation of irregular tau protein is likely one of the hallmark pathologies.

Additional information evaluation is ongoing in relation to the 1-year open label section of the trial, secondary endpoints together with MRI volumetric mind scans, and exploratory endpoints. A abstract of the LUCIDITY research protocol has just lately been revealed in The Journal of Prevention of Alzheimer’s Disease http://dx.doi.org/10.14283/jpad.2022.63).



The TauRx group of firms was established in 2002 in Singapore, persevering with a partnership with the University of Aberdeen, with major analysis amenities and operation primarily based in Aberdeen, UK. The firm has devoted the previous twenty years to growing remedies and diagnostics for Alzheimer’s and different neurodegenerative illnesses resulting from protein aggregation pathology.

Alzheimer’s dementia is a number one reason behind loss of life all through the world and probably the most vital public well being points to be addressed globally. TauRx will contribute to addressing this unmet want with information from LUCIDITY and pursuit of Medicines and Healthcare merchandise Regulatory Agency (MHRA) approval via the Innovative Licensing and Access Pathway (ILAP), having been granted an Innovation Passport, the primary stage of the method, in May this yr. 

TauRx plans to submit HMTM for regulatory approval within the US and Canada in 2023, with different territories to comply with, according to its total plans to commercialise HMTM and pursue scientific trials in different associated neurodegenerative illnesses.



Through devoted analysis packages, it’s understood that sure age-related elements result in misfolding and aggregation of tau proteins, and the next formation of tau tangles in Alzheimer’s. These tangles disrupt and injury neuronal perform, a course of that begins a few years earlier than signs of dementia are seen. Tau pathology has been confirmed to correlate with the scientific decline (lack of reminiscence and skill to care for oneself) generally seen in folks with Alzheimer’s, establishing it as an vital goal for remedy. HMTM is a tau aggregation inhibitor, which successfully crosses the blood mind barrier to focus on the supply of this damaging course of.





Cision View authentic content material:https://www.prnewswire.co.uk/news-releases/taurx-announces-results-from-phase-3-alzheimers-disease-study-lucidity-assuring-path-for-regulatory-submissions-301641617.html

Source link


Please enter your comment!
Please enter your name here